Orthocell Ltd (ASX: OCC) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Orthocell Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Orthocell Ltd (ASX: OCC)
Latest News
Healthcare Shares
Orthocell (ASX:OCC) share price surges 13% on study success
Healthcare Shares
Why the Orthocell (ASX:OCC) share price is flying higher today
Healthcare Shares
Here's why the Orthocell (ASX:OCC) share price is on the move today
Healthcare Shares
The Orthocell (ASX:OCC) share price is on the rise today. Here's why
Share Market News
Why the Orthocell (ASX:OCC) share price is edging higher today
Share Market News
Why is the Orthocell (ASX:OCC) share price falling today?
Share Market News
Why the Orthocell (ASX:OCC) share price is on the rise
Share Market News
Why the Orthocell (ASX:OCC) share price is rocketing 23% higher
Share Market News
Why the Orthocell (ASX:OCC) share price has popped 6% today
Share Market News
Why the Orthocell (ASX:OCC) share price is edging higher today
Share Market News
Orthocell (ASX:OCC) share price jumps 17% on positive clinical trials
Share Market News
The Orthocell share price is going nuts on claims of a blockbuster medical breakthrough
OCC ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
---|---|---|---|---|---|
YesNo |
About Orthocell Ltd
Orthocell Ltd is a regenerative medicine company. The company is engaged in the development and commercialisation of cell therapies and related technologies. Its product includes CelGro is a naturally derived collagen medical device for tissue repair and Ortho-ATI is a first-in-class cell therapy for the treatment of chronic tendon injuries.
OCC Share Price History Data provided by Morningstar.
Date | Close | Change | % Change | Volume | Open | High | Low |
---|---|---|---|---|---|---|---|
28 Mar 2024 | $0.39 | $0.00 | 0.00% | 212,313 | $0.39 | $0.40 | $0.39 |
27 Mar 2024 | $0.39 | $0.01 | 2.63% | 2,529 | $0.39 | $0.39 | $0.39 |
26 Mar 2024 | $0.38 | $-0.01 | -2.56% | 235,934 | $0.40 | $0.41 | $0.38 |
25 Mar 2024 | $0.39 | $-0.01 | -2.50% | 143,728 | $0.41 | $0.41 | $0.39 |
22 Mar 2024 | $0.40 | $0.01 | 2.56% | 34,872 | $0.40 | $0.40 | $0.39 |
21 Mar 2024 | $0.39 | $-0.01 | -2.53% | 219,903 | $0.39 | $0.39 | $0.38 |
20 Mar 2024 | $0.40 | $-0.01 | -2.50% | 4,000 | $0.41 | $0.41 | $0.40 |
19 Mar 2024 | $0.40 | $0.01 | 2.56% | 117,242 | $0.39 | $0.40 | $0.39 |
18 Mar 2024 | $0.39 | $-0.02 | -4.94% | 197,329 | $0.40 | $0.40 | $0.39 |
15 Mar 2024 | $0.41 | $0.00 | 0.00% | 22,080 | $0.40 | $0.42 | $0.40 |
13 Mar 2024 | $0.41 | $-0.01 | -2.41% | 48,789 | $0.40 | $0.42 | $0.40 |
12 Mar 2024 | $0.42 | $0.02 | 5.00% | 58,552 | $0.40 | $0.42 | $0.40 |
11 Mar 2024 | $0.40 | $-0.01 | -2.47% | 68,234 | $0.41 | $0.41 | $0.40 |
08 Mar 2024 | $0.41 | $0.00 | 0.00% | 99,389 | $0.41 | $0.41 | $0.40 |
07 Mar 2024 | $0.41 | $0.01 | 2.50% | 32,452 | $0.41 | $0.41 | $0.41 |
06 Mar 2024 | $0.40 | $-0.01 | -2.44% | 159,044 | $0.41 | $0.41 | $0.40 |
05 Mar 2024 | $0.41 | $0.00 | 0.00% | 253,093 | $0.41 | $0.42 | $0.41 |
04 Mar 2024 | $0.41 | $-0.01 | -2.38% | 15,590 | $0.42 | $0.42 | $0.41 |
01 Mar 2024 | $0.42 | $-0.01 | -2.35% | 132,317 | $0.42 | $0.42 | $0.41 |
29 Feb 2024 | $0.43 | $-0.01 | -2.33% | 26,720 | $0.43 | $0.43 | $0.42 |
28 Feb 2024 | $0.43 | $0.01 | 2.38% | 106,320 | $0.42 | $0.43 | $0.42 |
27 Feb 2024 | $0.42 | $0.00 | 0.00% | 54,317 | $0.42 | $0.43 | $0.42 |
Director Transactions Data provided by Morningstar.
Date | Director | Type | Amount | Value | Notes |
---|---|---|---|---|---|
17 Jan 2024 | Kim Beazley AC | Issued | 2,000,000 | $820,000 |
Issue of options.
|
20 Nov 2023 | Fiona Wood | Issued | 2,000,000 | $820,000 |
Issue of options.
|
15 Nov 2023 | John Wielen | Issued | 250,000 | $91,250 |
Issue of securities.
|
07 Nov 2023 | Paul Anderson | Issued | 500,000 | $192,500 |
Issue of options.
|
30 Oct 2023 | John Wielen | Buy | 20,000 | $7,239 |
On-market trade.
|
13 Jun 2023 | Paul Anderson | Buy | 9,907 | $3,516 |
On-market trade.
|
09 Jun 2023 | Paul Anderson | Buy | 31,343 | $11,254 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
Name | Title | Start Date | Profile |
---|---|---|---|
Professor Fiona Melanie Wood | Non-Executive Director | Nov 2023 |
--
|
Mr Paul Frederick Anderson | Managing Director | Mar 2006 |
Mr Anderson has over 20 years' experience in the medical device and regenerative medicine fields with experience in bridging the gap between research and clinical practice in the development of emerging medical technologies. He also has experience in the establishment of GMP manufacturing facilities and scale-up activities for cell therapies and biological medical devices, and the associated regulatory filings.
|
Dr Ravi Thadhani | Non-Executive Director | Mar 2023 |
Dr Thadhani has experience in patient care, advancing novel research programs, US regulatory pathways and commercialisation of devices and therapeutics. He served on multiple US FDA advisory committees in the musculoskeletal, cardiovascular and renal sectors providing expert guidance to the FDA and companies regarding the regulatory requirements for approval of medical devices and therapeutics, High-profile healthcare administration roles, most recently professor of medicine at Harvard Medical School and chief academic officer and dean for faculty affairs for Mass General Brigham hospital, research enterprise Expert advisor to multiple global pharmaceutical companies including Sandoz, Shire, Novartis, Celgene, Bayer and Reata on clinical trial design, execution and data monitoring Co-author of more than 300 scientific publications.
|
Mr John Van Der Wielen | Non-Executive ChairmanNon-Executive Director | Jun 2023 |
Mr Wielen has 35 years international experience in wealth management, private banking, investments, and insurance, in the UK, Luxembourg, Malaysia and Australia. He has held senior executive positions with several national and global financialservices groups. Most recently Mr Van Der Wielen wasthe CEO and MD of HBF Health Ltd for over five years. Mr Van Der Wielens other previous executive positions include CEO (UK & International) of Friends Life UK, Managing Director (Wealth) of ANZ, CEO of Clerical Medical, Halifax Life & Heidelberger Leben and CEO of Lloyds Banking Group/HBOS Plc.
|
Hon Kim Beazley AC | Non-Executive Director | Jan 2024 |
Mr Beazley is a former Australian politician and diplomat, serving as a Minister in the Hawke and Keating Labor Governments holding the portfolios of Defence, Finance and Special Minister of State, among others. Mr Beazley has also served as Deputy Prime Minister, Leader of the Australian Labor Party and Leader of the Opposition and, during his time in office, on parliamentary committees covering Intelligence, Foreign Affairs, Defence and Trade. He was appointed a Companion of the Order of Australia in 2009 for service to the Parliament of Australia and was appointed the 33rd Governor of Western Australian in 2018, serving in this role until 2022. Mr Beazley served as Ambassador to the United States of America between 2010 and 2016.His commercial service currently extends to Chair of the Perth US Asia Centre Board; Board Member of Luerssen Australia; Adviser to Lockheed Martin Australia; Chair of the Council for the Australian War Memorial; and Adviser to TG & Associates.
|
Mr Peter Webse | Company Secretary | Mar 2023 |
-
|
Peter Webse | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
Name | Shares | Capital |
---|---|---|
Ming Hao Zheng & Fan Ying | 6,805,886 | 3.45% |
Mr Paul Frederick Anderson & Ms Nicole Jane Telford | 6,233,335 | 3.16% |
Mr Qixiao Zhou | 5,996,241 | 3.04% |
Mr Jia Xun Xu | 5,299,107 | 2.69% |
Sandhurst Trustees Ltd | 4,913,939 | 2.49% |
Wenola Pty Ltd | 3,934,058 | 1.99% |
Mr Patrick John McHale | 3,657,147 | 1.85% |
Hsbc Custody Nominees (Australia) Limited | 3,287,549 | 1.67% |
Citicorp Nominees Pty Ltd | 2,057,820 | 1.04% |
Sankofa Strategic Equity Fund Limited | 1,962,000 | 0.99% |
Mr Tony Athas & Mrs Angela Athas | 1,600,000 | 0.81% |
Dr John Clifford Philpott | 1,560,216 | 0.79% |
Dr John Clifford Philpott & Mrs Rebecca Anne Philpott | 1,508,135 | 0.76% |
Mr Vance Clark Moore | 1,350,000 | 0.68% |
BNP Paribas Nominees Pty Ltd | 1,242,770 | 0.63% |
Mr Paul John Van Dyk | 1,074,275 | 0.54% |
Mr Bryan F Short | 1,068,200 | 0.54% |
Aris Nominees Pty Ltd | 1,042,816 | 0.53% |
Bond Street Custodians Limited | 1,000,000 | 0.51% |
Murdoch Ventures Pty Ltd | 923,851 | 0.47% |